Development Of A Subcutaneous Immunotherapy (SCIT) With A Modified Peanut Extract Formulation For The Treatment Of Peanut Allergy

Project: Commissioned research

Project Details

Description

A First-in-human, Randomized, Double Blind, Placebo Controlled, Single-centre Study to Assess the Safety and Tolerability of HAL-MPE1 in Patients With Peanut Allergy
Short titleHAL-MPE1 First-in-human
StatusFinished
Effective start/end date2014/06/01 → 2015/06/30

Collaborative partners

  • HAL Allergy Group
  • Odense University Hospital (lead)